Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T88483
|
|||||
Target Name |
microRNA hsa-miR-155 (MIR155)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 5 Target-related Diseases | + | ||||
1 | Keloid/hypertrophic scar [ICD-11: EE60] | |||||
2 | Mycosis fungoides [ICD-11: 2B01] | |||||
3 | Diffuse large B-cell lymphoma [ICD-11: 2A81] | |||||
4 | Mature B-cell leukaemia [ICD-11: 2A82] | |||||
5 | Systemic sclerosis [ICD-11: 4A42] | |||||
BioChemical Class |
Non-coding RNA target
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
1 | Cobomarsen | Drug Info | Phase 2 | Cutaneous T-cell lymphoma | [2] | |
2 | MRG-201 | Drug Info | Phase 2 | Keloid | [3] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 1 Inhibitor drugs | + | ||||
1 | Cobomarsen | Drug Info | [1], [4] | |||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | MRG-201 | Drug Info | [5] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 2 | ClinicalTrials.gov (NCT03837457) PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study (PRISM). U.S. National Institutes of Health. | |||||
REF 3 | ClinicalTrials.gov (NCT03601052) Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids. U.S. National Institutes of Health. | |||||
REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.